Diversified portfolio of drug discovery projects
The projects currently worked on at the LDC are as diverse as the institutes contributing them to the portfolio. The indications include cancer, neurodegenerative diseases, metabolic syndrome, infectious diseases and other conditions with high unmet clinical needs. In all cases, the LDC continues to collaborate closely with the scientific experts of the project at the respective institute, in order to integrate existing knowledge into the drug discovery phase. Systematic program diversification balances the inherent risks and benefits associated with drug discovery. This ensures significant opportunities for LDC's sustainability and future growth.
Priority on innovation
In selecting projects for drug discovery partnerships, the LDC places first priority on the quality of research, its medical and commercial potential, and innovativeness. Overall, the LDC aims to establish a risk-diversified, well-staged pipeline of highly-differentiated projects that address new targets or pathological processes, have novel modes of action or build on new chemical scaffolds.
